Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza Expands Facility in Switzerland | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Lonza Expands Facility in Switzerland

New facility will provide mid-scale commercial manufacturing to multiple customers and in particular, serve the growing needs of Servier.

By: Contract Pharma

Contract Pharma Staff

Lonza is expanding its microbial manufacturing facility in Visp, Switzerland. The new facility will provide mid-scale commercial manufacturing to multiple customers and in particular, serve the growing needs of Servier, an independent international pharmaceutical company and long-term Lonza partner.
 
Servier and Lonza have recently signed a long-term extension to the manufacturing agreement for L-asparaginase, produced at Lonza since 2009. The extension and expansion of the collaboration will provide Servier with the additional capacity required to provide treatment to many more patients with acute lymphoblastic leukemia (ALL), a cancer of the white blood cells. Servier intends to expand access to asparaginase-based multi-agent chemotherapeutic regimens.
 
The new facility will be the sixth to be housed in Lonza’s new biopark in Visp, Switzerland, currently under construction. Lonza launched Ibex Solutions in 2018 to offer custom-tailored manufacturing solutions across a broad range of technologies while minimizing time to market with pre-built shells and infrastructure. The new mid-scale (3,000L) microbial facility will tap into existing central utilities and labs and will complement the existing small-scale (1,000L) and large-scale (15,000L) assets in Visp.
 
The facility is expected to be operational in the second half of 2022 and Lonza expects to add 100 new staff to the existing, highly-experienced microbial team.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters